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Abstract
Objectives: To retrospectively analyze the clinical outcome of a totally biological composite stentless aortic valved
conduit (No-React
® BioConduit) implanted using the Bentall procedure over ten years in a single centre.
Methods: Between 27/10/99 and 19/01/08, the No-React
® BioConduit composite graft was implanted in 67
patients. Data on these patients were collected from the in-hospital database, from patient notes and from
questionnaires. A cohort of patients had 2D-echocardiogram with an average of 4.3 ± 0.45 years post-operatively
to evaluate valve function, calcification, and the diameter of the conduit.
Results: Implantation in 67 patients represented a follow-up of 371.3 patient-year. Males were 60% of the operated
population, with a mean age of 67.9 ± 1.3 years (range 34.1-83.8 years), 21 of them below the age of 65. After a
mean follow-up of 7.1 ± 0.3 years (range of 2.2-10.5 years), more than 50% of the survivors were in NYHA I/II and
more than 60% of the survivors were angina-free (CCS 0). The overall 10-year survival following replacement of the
aortic valve and root was 51%. During this period, 88% of patients were free from valved-conduit related
complications leading to mortality. Post-operative echocardiography studies showed no evidence of stenosis,
dilatation, calcification or thrombosis. Importantly, during the 10-year follow-up period no failures of the valved
conduit were reported, suggesting that the tissue of the conduit does not structurally change (histology of one
explant showed normal cusp and conduit).
Conclusions: The No-React
® BioConduit composite stentless aortic valved conduit provides excellent long-term
clinical results for aortic root replacement with few prosthesis-related complications in the first post-operative
decade.
Keywords: aorta and aortic valve disease, aortic valved conduit, aortic root replacement, Bentall?’?s operation, Bio-
Conduit, detoxified tissue, homografts, autografts
Introduction
T h ea o r t i cr o o tr e p l a c e m e n tb yt h eB e n t a l l ’s procedure,
described in 1968 [1], has been refined over time [2-4] and
still represents the preferred treatment for patients with
ascending aortic aneurysm and aortic valve disease in
whom the David’so rY a c o u b ’s operation cannot be per-
formed. Initially, the use of composite grafts with mostly
mechanical valves was considered a good treatment, how-
ever the 10-year results are less than desirable [2,5]. This
is mostly because of the complications of anticoagulation
and low, but consistent, rates of infection that require
removal of the Dacron graft, which carries a high rate of
mortality [4,6]. In the presence of infection, replacement
of the synthetic graft with a biological conduit is needed
[6,7]. Therefore, there is a need to determine the “ideal”
valved conduit, preferably totally biological, not requiring
anticoagulation, and durable for all patient ages.
Among the biological conduits, allografts (also known
as homografts) and pulmonary autografts (Ross proce-
dure) have been considered for aortic root replacement,
but the former are not always available and the latter is
not always possible. However, short-term follow-up
studies have clearly shown that, when compared to the
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monary autografts have advantages only early after
implantation [5], because allografts seems to have age-
related limited durability [8] and after eight years fol-
low-up the pulmonary autografts’ freedom from moder-
ate or severe regurgitation is below 75%, and freedom
from dilatation is between 10-15% [9]. Furthermore,
Pasquali et al. have shown that pulmonary autografts in
the aortic position dilate for up to 60% of patients at 6
years follow-up [10]. Such a high rate of dilatation
would lead to progressive rates of aortic valve dysfunc-
tion, a process that appears to start only after 3 years
[9-11]. The causes of these detrimental changes are not
fully elucidated but Schoof et al. [11] performing histo-
logical analysis on explanted pulmonary autografts from
the Ross procedure demonstrat e dt h a tt h ee l a s t i ct i s s u e
of the autograft had been slowly substituted with fibrous
material, including both the conduit wall and the valve
cusps, a “degeneration” considered as a negative “remo-
delling” process. It is clear that biological valved con-
duits alternative to allografts and pulmonary autografts
are much needed, having in mind that the “ideal” bio-
conduit should require no anticoagulation, can be
implanted in patients of all ages, and should have no
structural changes over the years. In addition, the ideal
conduit should resist infection.
The No-React
® BioConduit is a valved conduit made
from bovine pericardium made with the aim to resist
foreign body reaction and degeneration without needing
anticoagulation. Previous experimental animal studies
have shown that No-React
® tissue causes no foreign
body reaction, leading to a resistance to calcification
and degeneration [12]. Further studies using No-React
®
tissue as a patch for the Norwood procedure caused no
anti-HLA antibodies whereas allografts induced the pro-
duction of antibodies [13]. Indeed, clinical studies with
No-React
® valves, receiving an identical treatment to
the No-React
® B i o C o n d u i t ,h a v es h o w nah i g hr e s i s -
tance to infection [14,15]. However, a recent report has
warned on the possibility that this valved conduit may
undergo degeneration [16]. For a number of years, the
No-React
® BioConduit has been used in our institution
in patients with low life expectancy and advanced dis-
ease of the aortic valve and root in whom the implanta-
tion of other valved conduits was not advisable or
possible. Therefore, in this study, we have investigated
the long-term clinical results with the Bentall procedure
using the No-React
® BioConduit (BioIntegral Surgical,
Inc., Canada, formerly manufactured by Shelhigh) over a
10-year period in high risk patients in a single centre.
Patients and Methods
Between October 1999 and January 2008, 67 patients
with significant aortic valve and root pathology received
aN o - R e a c t
® BioConduit. The preoperative characteris-
tics of the study population are shown in Table 1. Of
them, 40 were males (60%) and 27 females (40%) with a
mean age of 67.9 ± 1.3 years (range 34.1-83.8 years),
with 21 being below the age of 65. This also shows that
approximately 40% of the patients suffered from angina
Table 1 Patients’ characteristics
N valid
Age at surgery (mean; SD) 67 67.9 (10)
Range: 34-84
Females 67 27 (40.3%)
BMI (mean; SD) 62 26.2 (4.6)
Range: 14-38
Associated conditions
DM 67 1 (1.5%)
Hypertension 67 34 (50.7%)
Smoking status 67
Never 29 (43.3%)
Ex -smoker 31 (46.3%)
Current 7 (10.4%)
Renal dysfunction 67 3 (4.5%)
Chronic Pulmonary Disease 67 11 (16.4%)
Cerebrovascular disease 67 5 (7.5%)
Peripheral vascular disease 67 4 (6%)
Previous Q wave MI 67 2 (3%)
Preoperative clinical status
Angina status (CCS class) 67
0 39 (58.2%)
1 8 (11.9%)
2 11 (16.4%)
3 9 (13.4%)
40
Dyspnea status (NYHA class) 67
1 14 (19.9%)
2 23 (34.3%)
3 23 (34.3%)
4 7 (10.4%)
Congestive heart failure 67
Never 42 (62.7%)
Now 18 (26.9%)
Past 7 (10.4%)
Neurological dysfunction 67 2 (3%)
Preop arrythmias (AF/Flutter) 67 8 (11.9)
Left ventricular ejection fraction 67
> 50% 52 (77.6%)
30-50% 9 (13.4%)
< 30% 6 (9%)
Critical preoperative state 67 13 (19.4%)
Preoperative pacemaker 67 2 (3%)
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mately 40% were or had previously experienced conges-
tive heart failure with 20% of them being in a critical
preoperative state. The advanced cardiac disease pre-
sented at the time of surgery was reflected by a high
logistic EuroSCORE with a mean of 46.8.
Surgical Technique
Surgical procedures were performed under standard
anesthetic protocol, operative techniques and post-
operative care. Briefly, patients were given Temazepam
20 mg and ranitidine 150 mg as premedication 2 hours
before their scheduled operation. Intravenous access
was established in the induction room, before the
patients were preoxygenated and monitored with ECG,
pulse oximetry and arterial line pressure tracing.
Anesthesia was then induced with fentanyl 5-10 μg/kg,
midazolam 0.05-0.1 mg/kg and rocuronium 1 mg/kg,
and maintained with O2/air mixture and isoflurane to
achieve a Bispectral Index System reading of less than
50. Patients were then intubated and a central venous
catheter was inserted. All operations were performed
through a median sternotomy using standard techniques
with cardiopulmonary bypass (CPB) under full heparini-
zation (3-4 mg/kg intravenously), and regular doses of
cold blood cardioplegia (ratio of blood to St. Thomas’
cardioplegic solution No1 of 4:1. 1000 ml was given
during the first dose, subsequently 500 ml was given at
20-30 minutes interval). Following the opening of the
aorta the aortic valve was excised. The dilated aortic
root and ascending aorta were removed and the coron-
ary ostia were dissected free. Following this, the appro-
priate No-React
® BioConduit size was anastomosed to
the aortic annulus with a continuous or interrupted
sutures, then the coronary buttons were attached to the
graft and finally the distal end of the conduit was ana-
stomosed to the distal ascending aorta. In some cases in
which the distal aorta was aneurysmatic, a woven
Dacron graft with a side branch for reinstating arterial
flow was inserted first using circulatory arrest at 17°C
(oesophagus temperature) without utilizing cerebral
perfusion.
Data Collection and Postoperative Follow-up
Clinical outcomes were investigated for a mean follow-
up of 7.1 ± 0.3 years (range of 2.2-10.5 years) and
reported following the AATS/STS/EACTS 2008 guide-
lines [17]. Patients’ data were obtained from hospital
records, telephone interview and mailed questionnaire.
The occurrence of death was obtained by reviewing the
data from the Office of National Statistics Registry and
contacting relatives or their general practitioners. The
study, as well as the use of patient’s data for research
purposes and publication, was approved by the local
Ethics Committee and, because this was a retrospective
analysis of a well established surgical procedure and the
investigations were performed as part of the standard
care, patient’s consent was not required.
The echocardiographic findings were collected from
the existing records and the aortic valve pathology was
qualitatively graded according to American Society of
Echocardiography guidelines.
Statistics and Expression of Results
Discrete variables are presented as number and as per-
centage. Continuous variables are presented as mean ±
standard deviation (SD) or interquartile range depending
on the normality deviation of the underlying distribu-
tion. Mean survival was estimated using Kaplan-Meier
method. Three events were considered for the analyses:
total mortality, cardiac mortality, and valve conduit
related mortality. To estimate mean survival free from
cardiac related fatal events those patients who died from
non-cardiac causes were censored at the time of death.
To estimate mean survival free from valve-conduit
related fatal events, those patients who died from other
causes considered non related with valve-conduit com-
plications were also censored at the time of death.
Results
Table 2 shows the surgical data. Up to 1/3 of the
patients were operated as urgent, emergent or as a sal-
vage procedure. 80.6% of the patients had an aneurysm
of the aortic root and ascending aorta, 13.4% presented
with acute dissection type A and 6% infection. The most
used No-React
® BioConduit graft sizes were the 25 and
27 mm diameter. Also up to 1/3 of the patients received
an associated surgical procedure with 17 requiring cor-
o n a r ya r t e r yb y p a s sg r a f t i n g( C A B G )w i t ht h el e f ti n t e r -
nal mammary artery (IMA) or saphenous vein grafts
(SVGs). In those with vein grafts, the proximal end of
the SVG was attached to the ascending aorta through
an opening made in the No-React
® BioConduit graft.
The operative times (cardiopulmonary bypass, aortic
cross-clamp and circulatory arrest) are also shown in
Table 2. None of the patients were anticoagulated with
warfarin but they received aspirin (75 mg/day) for life.
Table 1 Patients’ characteristics (Continued)
Extent of coronary disease 67
Grossly normal 55 (82.1%)
Single vessel 5 (7.5%)
Double vessel 4 (6%)
Triple vessel 3 (4.5%)
Left main stem disease 2 (3%)
Logistic EuroSCORE (mean;SD) 67 46.8 (19.3)
Logistic EuroSCORE (P25, P50, P75) 67 31.2; 45.3; 58.8
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Eight patients (11.9%) died within the 30-day postopera-
tive period. All of these patients were at an advanced
state of disease: 5 patients were in cardiogenic shock, 1
patient had active aortic endocarditis, and 2 patients
had complicated type A dissection of the aorta.
Although the case with endocarditis is considered valve-
related, the patient was in septic shock at the time of
surgery and died the same operative day.
As shown in Table 2 atrial fibrillation was the com-
monest postoperative complication followed by develop-
ment of low cardiac output. Three patients suffered
from cerebral ischemic attacks, all of them resolving
without permanent neurological deficit within a week
and only 2 patients were re-operated for surgical bleed-
ing non-related to the valved conduit.
Late results
Figure 1 shows that the overall 10-year survival following
replacement of the aortic valve and root was 51% (mean
survival time: 6.6 years; 95% CI 5.5-7.7). It also shows
that the actuarial freedom from cardiac death was 65% at
10 years including operative mortality (mean survival free
from cardiac related mortality: 7.6 years; 95% CI 6.5-8.7)
whilst the actuarial freedom from device-related mortal-
ity was 88% for the same period (mean survival free from
valve-conduit related mortality: 9.4 years; 95% CI 8.7-
10.2), this including operative mortality.
Table 2 Surgical data and postoperative complications
N valid
Operative priority 67
Elective 45 (67.2%)
Urgent 15 (22.4%)
Emergency 4 (6%)
Salvage 3 (4.5%)
Number of operations 67
First 56 (83.6%)
Second 10 (14.9%)
Third 1 (1.5%)
Type of aortic valve lesion 67
Stenotic 18 (26.9%)
Regurgitant 35 (52.2%)
Mixed 14 (20.9%)
Explanted valve 67
Native 52 (77.6%)
Bioprosthesis 7 (10.4%)
Mechanical 7 (10.4%)
Homograf 1 (1.5%)
Aortic valve pathology 67
Calcific degeneration 29 (43.3%)
Myxomatous degeneration 11 (16.4%)
Prosthetic valve failure 9 (13.4%)
Congenital 5 (7.5%)
Annuloaortic ectasia 3 (4.5%)
Dissection 3 (4.5%)
Infection 2 (3%)
Rheumatic 1 (1.5%)
Other degenerative 1 (1.5%)
Unknown 3 (4.5%)
Pathology of the aorta 67
Aneurysm 54 (80.6%)
Dissection 9 (13.4%)
Infection 4 (6%)
No-React
® BioConduit size 67
20 1 (1.5%)
21 5 (7.5%)
23 7 (10.4%)
25 23 (34.3%)
27 24 (35.8%)
29 4 (6%)
31 1 (1.5%)
Unknown 2 (3%)
Other cardiac procedures 67
CABG 17 (24.4%)
Replacement/repair of other valves 3 (4.5%)
LV Aneurysmectomy 1 (1.5%)
Other procedures 5 (7.5%)
Table 2 Surgical data and postoperative complications
(Continued)
CBP time (min); mean (SD) 65 183 (86)
Range: 96-554
CPB time (P25, P50, P75) 135; 155; 207
Aortic XC time (min); mean (SD) 65 130 (45)
Range: 63-275
Aortic XC time (min) (P25, P50, P75) 99.5; 117; 146.5
Circulatory arrest time; mean (SD) 28 33.71 (17)
Range: 4-69
Circulatory arrest time (P25, P50, P75) 24.2; 28.5; 43.7
Postoperative complications
Atrial fibrillation 67 17 (25.4%)
Low cardiac ouput 67 11 (16.4%)
Renal complication 67 5 (7.5%)
Neurological 67 3 (4.5%)
Implantation of PPM 67 3 (4.5%)
Pulmonary 67 2 (3%)
Infective complications 67 2 (3%)
G.I. complications 67 2 (3%)
Re-sternotomy for bleeding 67 2 (3%)
Sternal resuturing 67 1 (1.5%)
Readmitted to ITU 67 1 (1.5%)
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up, more than 50% of the survivors were in NYHA I/II
and more than 60% of the survivors were angina-free
(CCS 0). During this period, no thromboembollic events
were recorded neither structural deterioration of the
valved conduit. However, there were two cases with
mild aortic regurgitation (+1 regurgitation only). In one
of them, fever was developed 9 months prior being
admitted to hospital in severe cardiogenic shock with
both stenosis and regurgitation and endocarditis was
diagnosed. She was urgently taken to the OR where an
abscess outside the conduit was compressing and dis-
torting and causing both stenosis and regurgitation.
Upon explantation the valve and the conduit looked
normal. Figure 2 shows the outflow and inflow of the
explanted graft, as well as histological analysis of the
valve. The pericardium of the conduit and the valve
were unaffected by the infection that was exclusively
located to the outside of the graft. Interestingly, the
valve cusps and the pericardium of the prosthesis
stained positive for Factor VIII immunoassay indicating
the covering of the graft by a monolayer of endothelial
cells. The source (human versus porcine) of the
endothelial cells on the graft was not investigated but it
will be expected that they are coming from the same
patient since the process of graft preparation eliminates
any endothelium of porcine origin. This case was the
only one reoperated in this series.
Echocardiographic findings
The echocardiografic findings (Tables 3 and 4) at last
follow-up (mean = 4.3 years) showed that, in the studied
patients, the valve function did not deteriorate and the
diameter of the conduit was not increased, with no evi-
dence of stenosis, dilatation, calcification or thrombosis
of the graft.
Discussion
The present study shows for the first time that the
totally biological No-React
® BioConduit graft affords
excellent long-term clinical results, with few graft-
related complications, in a high risk group of patients
(eg, elevated EuroScore) with short life expectancy. Dur-
ing the study period, no deterioration of the valve (eg,
calcification, rupture) and conduit (eg, dilatation, calcifi-
cation) were detected. These results are of clinical
importance for the surgery of the aortic root and in
some patients might represent a better alternative than
other synthetic or biological valved conduits.
The 10-year results of aortic root replacement using
composite grafts with mostly mechanical valves are less
than desirable [2,5], mainly due to complications with
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Figure 1 Kaplan-Meier curves of mortality.
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tion. There are several aortic valved conduits as alterna-
tive to a synthetic prosthesis with a mechanical aortic
valve prosthesis but they also present their own set of
specific issues that are discussed below. In biological
aortic valved conduits, preservation of the graft collagen
structure appears to be critical to avoid dilatation of the
conduit and incompetence of the prosthetic valve. Pul-
monary autografts have been shown to develop a high
incidence of both dilatation of the conduit and incom-
petence of the valve [9-11] and they may not be suitable
as substitute of the aortic root because their collagen
structure and content differs form that of the aorta. In
addition, in patients with cystic medial degeneration of
the aorta, particularly those with bileaflet aortic valve
and those with Marfan’s syndrome, the pulmonary
artery may also present with degenerative changes of
the wall [18] that may make the autograft unsuitable for
use as a substitute of the aortic root. Indeed, dilatation
and regurgitation of the pulmonary autograft constitute
the primary cause of failure and the principal reason for
reoperation after the Ross procedure [9-11]. To over-
come this problem, it has been proposed that in patients
with bileaflet aortic valve the pulmonary autograft
should be implanted with the use of the aortic root
inclusion technique instead of aortic root replacement
and that both the aortic annulus and the sinotubular
junction should be fixed with a strip of Dacron fabric
[19]. When an inclusion technique is not feasible, pul-
monary autograft reinforcement with a Valsalva Gel-
weave Dacron tube (Terumo Cardiovascular Systems
Inc, Ann Arbor, Mich) has been recommended as an
option [20]. However, even with the use of the aortic
root inclusion techniques, valve prolapse still remains
the main cause of failure of the pulmonary autograft
[21]. A systematic review of evidence on outcome after
the Ross procedure has shown that, although the Ross
procedure provides satisfactory results for both children
Figure 2 Outflow and inflow of the explanted graft, as well as histological analysis of the valve. Panel A shows the outflow of the valve,
with totally normal looking, coapting cusps; Panel B shows the outflow, and the inflammatory reaction to the abscess which was responsible for
valvular distortion is seen in the upper right hand corner; Panel C shows the H+E histological slide, showing normal looking pericardium of the
conduit and the inflammatory cells of the abscess cavity; Panel D shows the Factor VIII immunoassay of one of the cusps, positive for
monolayered endothelial cells.
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surgeon executing the procedure, durability limitations
become apparent by the end of the first postoperative
decade, in particular in younger patients [21]. It is
worth mentioning that a broad spectrum of complex
reoperations may be required after the Ross procedure
which are associated with important morbididty [22].
The cause of the detrimental changes on pulmonary
autografts are not fully elucidated but Schoof et al.[ 1 1 ]
performing histological analysis on explanted specimens
from the Ross procedure demonstrated that the elastic
tissue of the autograft had been slowly substituted with
fibrous material, including both the conduit wall and
the valve cusps, a “degeneration” considered as a nega-
tive “remodelling” process. The observation of fibrous
hyperplasia of the ventricularis and changes in the cellu-
lar and extracellular matrix characteristics in pulmonary
autograft valve explants has lead to the suggestion that a
primary valve-related cause is involved in pulmonary
autograft valve failure [23].
Another alternative for the replacement of the aortic
root is the use of allografts; however, cryopreserved aor-
tic allografts are not easily available and also have an
age-related limited durability. Thus, it has been shown
that although the use of allografts for aortic valve repla-
cement is associated with low occurrence rates of most
valve-related events, over time the risk of structural
valve deterioration increases, which is comparable to
stented xenografts [24] and other aortic valve prostheses
Table 3 Echocardiography data prior to surgery (mean =
120 days; median = 90 days) and early (mean = 43.1
days; median= 7 days) and late (mean=4.3 years;
median= 4.4 years) after surgery
N
valid
Mean
(SD)
Range P25, P50,
P75
Aortic root diameter
(mm)
Preop 26 51 (14.3) 26-83 41; 50; 57
First echo post-op 18 34.6 (5.5) 25-49 31; 34; 38
Last echo post-op 15 33.6 (4.3) 25-40 30; 33.5; 37
LVIDd (mm)
Preop 11 64 (11.7) 45-78 53; 62; 75
First echo post-op 17 52 (8) 40-69 46; 52; 58
Last echo post-op 16 49 (7.3) 36-64 43; 48; 53
Aortic velocity (m/sg)
Preop 10 2.6 (0.9) 1.4-4.7 1.9; 2.3; 3.1
First echo post-op 34 2.1 (0.5) 1-3.2 1.5; 2; 2.3
Last echo post-op 20 1.97 (0.6) 0.9-3.8 1.6; 1.9; 2
Aortic max gradient
Preop 25 51 (31) 8.1-122 22; 50; 72
First echo post-op 38 17 (9.3) 4.3-42 10.3; 15.5; 21.2
Last echo post-op 26 16.2 (11) 3.5-59 10.6; 14.3; 18.3
Aortic mean gradient
Preop 16 23.7 (21) 4.4-77 8; 17.5; 34.2
First echo post-op 37 9.5 (4.3) 3.3-
23.3
5.8; 9; 12
Last echo post-op 22 9.4 (6.4) 3-34 6.1; 8; 9.4
Aortic V2 VTI
Preop 8 51 (26) 27-110 35; 41; 59
First echo post-op 35 34.4 (11) 17-62 26; 32; 40
Last echo post-op 16 37 (16) 25-91 28.4; 31; 40.1
LV ejection fraction
Preop 19
> 50% 8 (12%)
30-50% 8 (12%)
< 30% 3 (4.5%)
First echo post-op 15
>50% 8 (12%)
30-50% 2 (3%)
< 30% 5 (7.5%)
Last echo post-op 19
> 50% 16 (24%)
30-50% 2 (3%)
< 30% 1 (1.5%)
Table 4 Paired analysis for the first (mean = 43.1 days;
median= 7 days) and second (mean=4.3 years; median=
4.4 years) echocardiography investigations performed
after surgery
N valid Mean
(SD)
Range P25, P50, P75
Aortic root diameter (mm) N=7
First echo post-op 33.4 (2) 30-36 32; 33.7; 35
Last echo post-op 33.3 (3.1) 29-38 30; 33.5; 3
LVIDd (mm) N=1 0
First echo post-op 52 (10) 40-68 45.7; 46.4; 62
Last echo post-op 51 (7.7) 41-64 44; 49; 57
Aortic velocity (m/sg) N=1 3
First echo post-op 2.1 (0.5) 1.4-3.2 1.6; 2.1;2.5
Last echo post-op 2.1 (0.7) 0.9-3.8 1.6; 2; 2.3
Aortic max gradient N=2 0
First echo post-op 18 (10.4) 6-42 10; 15.5; 22.7
Last echo post-op 16 (12.2) 3.5-59 10.2; 14; 16
Aortic mean gradient N=1 8
First echo post-op 9.2 (5.2) 3.3-
23.3
5.5; 7.8; 11.2
Last echo post-op 9.7 (6.8) 3-34 6.7; 8; 9.3
Aortic V2 VTI N=1 3
First echo post-op 32.7 (11.4) 21-62 24; 29; 39.8
Last echo post-op 38.6 (17) 25-91 28.5; 33; 43.9
Abbreviations: left ventricular internal diameter in diastole - LVIDd; aortic V2 VTI
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valve, Medtronic Freestyle valve) [25]. Furthermore,
Smedira et al. reported the explantation of 46 allografts
after 5.6 ± 3.1 years follow-up in 744 patients whom
have received cryopreserved allografts with a mean age
of 49 ± 12 years. In this study, structural valve dete-
rioration was the most frequent cause (59% of the cases)
of valve-related reoperation after allograft aortic valve
replacement [26]. Therefore there is a considerable life-
time risk of reoperation, especially in young patients,
and, because of this, at some institutions the use of allo-
grafts only remains the preferred valve substitute for
patients with active aortic root endocarditis and for
patients in whom anticoagulation should be avoided.
The No-React
® BioConduit, being a completely biolo-
gical and readily available graft, is an excellent alterna-
tive to pulmonary autografts and allografts. The
BioConduit is easily handled facilitating its technically
insertion. The absence of clinical evidence for degenera-
tive changes of the No-React
® BioConduit graft seen in
our study may be explained by the manufacturing pro-
cess used. Thus, the recognition that glutaraldehyde and
formaldehyde are prerequisites for limiting calcification
and the importance of preservation of cross-linked col-
lagen for the durability of biological tissue [27] was fun-
damental to develop the method used in the No-React
®
BioConduit graft. In this process, heparin is used to lock
the glutaraldehyde residue, so that glutaraldehyde leach-
ing is abolished and its potential immunological reactiv-
ity is prevented [12], hence keeping all the advantages of
glutaraldehyde but abolishing its side effects.
O n ei m p o r t a n tf i n d i n go fo u rs t u d yw a st h er a r e
occurrence of infection of the No-React
® BioConduit
graft. One case with aortic endocarditis was in septic
shock at the time of surgery dying the following day;
therefore the lost of this patient cannot be attributed to
infection of the newly implanted graft. The only other
case presenting with late endocarditis was in fact a peri-
prosthetic abscess without affecting the graft. Clinical
studies with No-React
® valves, receiving an identical
treatment to the No-React
® BioConduit, have also
shown a high resistance to infection [14,15]. By contrast,
synthetic aortic valved conduits [7], pulmonary auto-
grafts [28] and allografts [29] have an important rate of
failure because of endocarditis. In the active phase of
allografts with endocarditis the operative mortality and
long-term prognosis are similar to those reported with
conventional prostheses [30]. The reason for the resis-
tance of No-React
® BioConduit and valve to infection is
not fully understood but the presence of endothelium
with No-React
® tissue on blood contacting surfaces has
been suggested as a potential explanation [31]. Our
results contrast with the recently reported degeneration
of the No-React
® BioConduit in 7 of the 115 cases
implanted with the prosthesis more than 1 year after
surgery [16]. Endocarditis was identified as the most
likely cause, although extensive microbiological exami-
nations did not reveal a causative organism [16]. During
the follow-up study period, we did not observed this
complication in none of the patients implanted with this
prosthesis. However, our study is up to 10 years and we
believe it would be required at least 15 to 20 years to
confirm whether the No-React
® BioConduit is really
resistant to degeneration and infection, a question that
probably should also be explored in a larger population
in prospective and randomized studies comparing the
No-React
® BioConduit with other biological conduits.
In conclusion, the present study has demonstrated
that the No-React
® BioConduit does not dilate or dete-
riorate and resists infection after 10-year follow-up.
Therefore, the No-React
® BioConduit may be a good
alternative to other conduits for surgery of the aortic
root in all age range.
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